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After recognition, NK cells can kill susceptible target cells through perforin-dependent mech-
anisms or by inducing death receptor-mediated apoptosis, and they can also secrete cytokines
that are pivotal for immunomodulation. Despite the critical role as effector cells against tumors
and virus-infected cells, NK cells have been implicated in the regulation of T cell-mediated
responses in different models of autoimmunity, transplantation, and viral infections. Here, we
review themechanisms described for NK cell-mediated inhibition of adaptive immune responses,
with spotlight on the emerging evidence of their regulatory role that shapes antitumor immune
responses.
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1 INTRODUCTION
NK cells constitute the third most abundant lymphoid cell popula-
tion in blood of humans. Evidence obtained from mouse studies and
the analysis of patients with rare primary immunodeficiencies char-
acterized by the absence of NK cells or the presence of function-
ally deficient NK cells unraveled their critical role during immunity
against viral infections.1–3 Experimental evidence obtained in mice
also positioned them as major players in antitumor immunity.4,5 In
humans, such role was inferred from a large longitudinal study where
an association between “natural cytotoxicity” in blood and suscepti-
bility to develop different malignancies was observed.6 NK cells also
exert immunoregulatory effects in different physiologic and patho-
logic conditions, skewing the adaptive immune response toward a Th1-
and cytotoxic CD8 T cell-mediated immune response.7–9 In addition,
it has been established that NK cells are relatively abundant in dif-
ferent tissues, contributing to the local immunosurveillance against
pathogens.10,11
The discovery of a new family of innate immune cells named innate
lymphoid cells (ILCs) that play an essential role in the initiation, reg-
ulation, and resolution of inflammation has led to a reclassification of
NK cells as one of the components of this extended family of innate
Abbreviations: DCs, dendritic cells; EAE, experimental autoimmune encephalomyelitis; EAU,
experimental autoimmune uveitis; HBV, hepatitis B virus; HCV, hepatitis C virus; ILCs, innate
lymphoid cells; LCMV, lymphocytic choriomeningitis virus; MCMV,murine cytomegalovirus;
NSCLC, non-small cell lung cancer; PD-L1, programmed death-ligand 1; Tfh, follicular helper
CD4 T cells; TIL, tumor-Infiltrating Lymphocytes; Treg, regulatory T cell.
immune cells of lymphoid lineage.12 All ILCs lack an antigenic recep-
tor and, with the exception of NK cells, are sparse in lymphoid organs,
but enriched inmucosa and skin.13
Although classically it was assumed that NK cells remain usually
in a nonactivated status or silenced due to the expression of a vast
array of inhibitory receptors, such as KIRs, NKG2A, 2B4, TIGIT, and
others, recent evidence obtained by single-cell transcriptome analysis
demonstrated that different human NK cell subpopulations from
bone marrow and blood express genes that indicate the occurrence
of a homeostatic activation.14 Nonetheless, when NK cells encounter
tumor or infected host cells that display a dysregulated expression of
ligands for activation receptors such as NKG2D, NKp46, and NKp30,5
NK cells usually become activated and trigger a cytotoxic response
against these susceptible target cells and also begin to secrete
cytokines (in particular IFN-𝛾) and chemokines.10,15 NK cells can kill
virus-infected or tumor cells through the release of lytic granules con-
taining granzyme and perforin or by inducing death receptor-mediated
apoptosis via the expression of FasL or TRAIL.16 Moreover, NK cells
become activated by diverse proinflammatory cytokines, in particular
IL-12, IL-15, and IL-18.17
From a functional perspective, mouse and human NK cells are
quite similar (both are cytotoxic and produce proinflammatory
cytokines). However, they differ in some phenotypic features. In
humans, NK cells are defined by the absence of expression of CD3
and by the expression of CD56 and CD16 (the FcR𝛾IIIa). According
to the expression of CD56 and CD16, they are further subdi-
vided into 2 major subpopulations.18 Nearly 90% of NK cells in
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peripheral blood exhibit a CD3−CD56dimCD16+ phenotype, and
exhibit a high content of perforin and granzymes (and consequently,
display a strong cytotoxic activity); the rest of NK cells in blood
display a CD3−CD56brightCD16dim/− phenotype, express CD25, and
mostly produce immunoregulatory cytokines in response to different
stimuli.18–22 These cells prevail in secondary lymphnodes and, through
the secretion of cytokines, instruct dendritic cells (DCs) to generate
Th1- and cytotoxic CD8 T cell-skewed responses, shaping in this way
the adaptive immunity.23,24 In vitro evidence and studies from cer-
tain primary immunodeficiencies indicate that CD56brightCD16dim/−
cells constitute a precursor of the most mature CD56dimCD16+
cells.25–29 However, in mice and because they do not express CD56,
NK cells are characterized as CD3−CD49b+ cells, but in some par-
ticular strains such as C57BL/6, they can also be characterized as
CD3−CD161b/CD161c+ cells (CD3−NK1.1+ cells).30 In addition, 4
subpopulations of mouse NK cells are currently recognized, based on
the expression of CD27 and CD11b, with phenotypes CD27−CD11b−,
CD27+CD11b−, CD27+CD11b+, and CD27−−CD11b+ from the most
immature to themost mature NK cell subpopulations.31,32
Although an array of diverse surface receptors confers NK cells
the ability to sense ligands expressed on target cells and respond
accordingly, NK cell also senses proinflammatory and immunosuppres-
sive cytokines produced by different cells of myeloid origin.33 More-
over, NK cells also express TLR and respond to the presence of their
specific ligands.34,35 In addition, cooperation between cytokines for
NK cell activation and development of effector function has been
described.9,36,37 Therefore, NK cells can integrate multiple signals
from their environment and adjust their effector functions to optimize
the extent of their response to pathogens and tumor cells.
Despite their critical role as effectors against tumors and
pathogens, more recently NK cells have been implicated in the
negative regulation of adaptive immune responses. In this review,
we discuss the role of NK cells regulating adaptive immunity both
in physiologic and in pathologic conditions, with their regulatory
functions during antitumor immunity on the spotlight.
2 REGULATORY FUNCTIONS OF NK CELLS
DURING INFECTIONS
During infections, strong adaptive immune responses need to be
tightly controlled to optimize efficient pathogen elimination while
protecting the host from immunopathology. Accumulating evidence
highlights the role of NK cells as regulators of adaptive immune
responses. Several reports show evidence of the ability of NK
cells to directly eliminate activated T cells in a perforin-dependent
manner.38,39 Early studies demonstrated that mouse CD4 and CD8 T
cells that have been activated by antigen presenting cells38 and human
CD4 and CD8 T cells activated after superantigen, alloantigen, or
specific antigenic peptide-stimulation,39 up-regulate the expression
of NKG2D ligands, which makes them susceptible to recognition and
elimination by IL-2-activated NK cells in a NKG2D- and perforin-
dependent manner in vitro.38,39 Moreover, the regulatory role of
NK cells was also appreciated in vivo in different physiopatholog
situations, as detailed in the next sections.
2.1 Regulatory functions of NK cells during
viral infections
Studies using lymphocytic choriomeningitis virus (LCMV) infection
unraveled that NK cells can negatively regulate the magnitude of the
antiviral response. LCMV constitutes an excellent experimental model
that has been widely used to address tissue-specific tolerance and its
underlying mechanisms.40,41 Although LCMV infection strongly acti-
vates NK cells, virus elimination is NK cell-independent.42 Besides, in
2B4-deficient LCMV-infected mice, NK cells were able to eliminate
activated CD8 T cells in vitro and in vivo, suggesting that 2B4-CD48
interactions protects CD8 T cells from NK cell-mediated killing dur-
ing viral infection.43 Also, NK cell-deficient (Nfil3−/−) mice or NK cell-
depleted wild-type mice infected with LCMV displayed an increased
virus-specific CD8 T cell response, resulting in earlier virus control. In
this setting, LCMV-specific T cells expressed NKG2D ligands, whereas
NKG2D was up-regulated and 2B4 was down-regulated on NK cells,
resulting in a negative regulation of T cell proliferation and IFN-𝛾 pro-
duction in a NKG2D and perforin-dependent manner.44 The use of
NCR1-deficient mice and transfer experiments showed that NK cells
can directly kill virus-activated CD4 and CD8 T cells during chronic
LCMV infection, in aNKp46-depedentmanner. In the absenceofNCR1
(that encodes for NKp46), CD8 T cells exhibited an enhanced effec-
tor response, which resulted in faster viral clearance accompanied by
severe immunopathology, supporting the notion that the regulatory
activity of NK cells is important to limit T cell-mediated damage to the
host.45 More recently, it was observed that LCMV-activated NK cells
can kill all activated CD4 subsets andCD8T cell in vitro and in vivo in a
perforin-dependent manner, yet the different T cell subsets showed a
hierarchy of sensitivity, being. Th0 and Th1 cells themost resistant and
regulatory T cell (Treg), Th17, Th2, and CD8 T cells the more sensitive
to NK cell cytotoxicity.46
Other viral infections also provided evidence for a regulatory
role of NK cells. Depletion of NK cells in murine cytomegalovirus
(MCMV)-infected mice resulted in enhanced IFN-𝛾 production by
CD4 and CD8 T cells, and CD8 T cell proliferation.42 Consistent with
an immunoregulatory role, NK cells from Noé mice (mice with a loss
of function mutation in NCR1 gene that display over-expression of
the Helios transcription factor) display an hyperreactive phenotype
and the ability to inhibit IFN-𝛾 production by CD4 and CD8 T cells in
MCMV-infected mice and the generation of a fully protective memory
T cell response to the intracellular bacteria Listeria monocytogenes.47
Remarkably, MCMV infection in mice recapitulates many aspects
of infection of humans with CMV.48 In both species, infection with
the corresponding CMV promotes the expansion of NK cells with
features of cells of the adaptive immune response characterized by
the expression of Ly49H in mice and CD94/NKG2C in humans.49
However, whether NKG2C+ human NK cells can display a putative
regulatory function during CMV infection remains unknown.
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Additional transfer experiments demonstrated that NK cells acti-
vated by LCMV, Pichinde virus, mouse hepatitis virus, or poly I:C could
eliminate LCMV-activated CD4 T cells. Reciprocally, LCMV-activated
NK cells were able to lyse CD4 T cells activated by infections with
LCMV, Pichinde virus, MCMV, mouse hepatitis virus, or vaccinia
virus.50 These results provided evidence that the killing of activated
CD4 T cells by activated NK cell during viral infections is a widespread
phenomenon. In these settings, activatedCD4Tcellswere significantly
more susceptible to NK cell-mediated elimination than activated CD8
T cells, presumably because of higher expression of CD48 on activated
CD8 T cells. However, as CD4 T cells provide help to generate CD8 T
cell responses to LCMV, NK cells also indirectly can regulate the mag-
nitude of CD8 T cell responses through the elimination of such CD4 T
cells.50 Nevertheless, the capacity ofNKcells to inhibit T cell responses
seems to relate to the virus ability to induceNKcell activation.NK cells
become poorly activated by vaccinia virus resulting in higher expres-
sion of NKG2A and lower expression of activation markers and effec-
tor molecules compared with the LCMV-activated NK cells, and these
NK cells exhibit a reduced ability to constrain CD4 T cell responses.51
Depending on the infective dose and the pathogen, NK cell-
mediated regulation of T cell activity may be beneficial or detrimen-
tal to the host. For example, NK cell depletion has minimal effect
on T cell-mediated immunity or immunopathology in mice infected
with low doses of LCMV-clone 13, a strain that generates chronic dis-
ease, or acutely infected with LCMV-Armstong, a strain that is spon-
taneously cleared after acute infection.50,52 In contrast, infection of
mice with high doses of LCMV-clone13, resulted in the accumulation
of exhaustedT cells that contributed to viral persistencebut prevented
fatal pathology, and this effect was not observed in NK cell-depleted
mice.50,52 Conversely, at medium doses of infection, NK cells fostered
T cell-mediated disease. Therefore, NK cells seem to act as a rheostat
that regulates themagnitude of antiviral T cell responses and critically
affect the outcome of the infection, which may result in resolution,
chronicity, or immunopathology.50
Type I IFN are key cytokines rapidly induced during viral infec-
tions that, in LCMV-activated antigen-specific T cells, can induce the
expression of ligands for NK cell inhibitory receptors such as classical
MHC-I molecules and Qa-1b53 and restrict the expression of NKp46
ligands,54 protecting activated T cells fromNK cell-mediated perforin-
dependent lysis. Also, type I IFN, by suppressing the up-regulation of
MCMV-induced NKG2D ligands on NK cells, protects NK cells from
fratricide through NKG2D and perforin-mediated elimination.55 In
humans, IFN-𝛽 signaling in CD4 T cells induces HLA-E expression,
rescuing them from NK cell-mediated elimination.56 Thus, type I
IFN signaling triggered during viral infections can attenuate T cell
susceptibility to NK cell-mediated elimination, and this phenomenon
may contribute to the adequate expansion of effector T cells required
to control the viral infections.
As mentioned above, NK cells can induce death receptor-mediated
apoptosis through expression of TRAIL and engagement of TRAIL
receptorsDR4 (TRAIL-R1) orDR5 (TRAIL-R2) on target cells.16 During
chronic MCMV infection of BALB/c mice, TRAIL+ NK cells accumulate
in the salivary glands, whereas activated CD4 T cells express NKG2D
ligands and TRAIL-R2, making them susceptible to NKG2D-mediated
recognition and TRAIL-dependent deletion by NK cells.57 Remarkably,
depletion of NK cells resulted in a faster resolution of the infection but
the resulting magnified inflammatory response resulted in an autoim-
mune disease similar to human Sjogren’s syndrome.57 In humans, a
similar mechanism aimed at controlling the magnitude of the antiviral
CD8 T cell response seems to operate in patients with chronic hep-
atitis B virus (HBV) infection. Accordingly, in chronic HBV-infected
patients, high expression of TRAIL was detected on liver NK cells,
whereas high expression of TRAIL-R2 was observed on HBV-specific
CD8 T cells, and this last population was further enriched in the liver
and susceptible to caspase-8-mediated apoptosis.58 Recently, a novel
nonapoptotic pathway for TRAIL signaling on NK cells was described
that involves an IL-15-induced TRAIL-mediated enhancement of
granzyme B production by NK cells that results in diminished CD8 T
cell responses due to T cell elimination in LCMV-infectedmice.59
In addition to their ability to directly eliminate T cells, NK cells
were shown to also indirectly suppress T cell responses through the
secretion of IL-10.60,61 Compared with the NK cells from healthy
donors, NK cells from individuals chronically infected with hepatitis
C virus (HCV) produce larger amounts of IL-10,62,63 which in turn
could inhibit DCmaturation.62 Likewise, NK cells from patients chron-
ically infected with HBV produce larger amounts of IL-10 than healthy
donors and monocytes exposed to HBV induced the differentiation of
IL-10-producing NK cells, which inhibited HBV-specific-T cell prolifer-
ation and IFN-𝛾 production in a IL-10-dependent manner.64
NK cells can also indirectly regulate B cell responses against LCMV
throughperforin-dependenteliminationof follicular helperCD4Tcells
(Tfh), and a subsequent inhibition of germinal center responses and
antibody generation.65,66
2.2 Regulatory functions of NK cells during
bacterial and parasite infections
Evidence about a regulatory function of NK cells during bacterial and
parasite infections are less abundant. In mice, NK cells are an early
source of IL-10 during systemic infections with Toxoplasma gondii or
Yersinia pestis. Systemic but not localized infections induced IL-12
production by DCs, which subsequently triggered IL-10 production
by NK cells that limited further production of IL-12.67 In contrast,
during L. monocytogenes infection, IL-10 production by NK cells is
driven by IL-18 in an IL-12-independent way,68 arguing that at least 2
different pathways can induce IL-10 secretion by NK cells. Addition-
ally, NK cell production of IL-10 during Leishmania donovani69 and L.
monocytogenes70 infection results in inhibition of protective immunity,
whereas during infection withMCMV, NK cell-derived IL-10 regulates
the magnitude of endogenous CD8 T cell responses and protects the
host fromCD8 T cell-dependent immunopathology.71
Aswithviruses,NKcells canalso indirectly regulateBcell responses
against bacteria through a similar mechanism that involves the limi-
tation of antibody production due to the elimination of Tfh cells that
inhibit the germinal center reactionduring L.monocytogenes,65 andalso
during immunization.72
4 ZWIRNER ET AL.
TABLE 1 Regulation of immune responses by NK cells during infections
Species Pathogen Target cell Molecules involved References
Mouse - LCMV - CD8 T cells
- CD4 T cells
- CD4 and CD8 T cells
- CD8 T cells and APC
- NK cells
- CD8 T cells
- CD4 T cells, Tfh and B cells
- NKG2D, 2B4 or NKp46, and perforin
- N/D
- Type I IFNs, NKp46, and perforin
- N/D
- Type I IFN, NKG2D, and perforin









- MCMV - CD4 and CD8 T cells
- NK cells
- CD4 T cells
- CD8 T cells
- N/D







- Toxoplasma gondii - DCs - IL-10 67
-Listeria monocytogenes - Inflammatorymyeloid cells - IL-10 68,70
- Leishmania donovani - N/D - IL-10 69
Human -Mycobacterium bovis - CD4 T cells - IL-10 61
- Chronic HCV - DCs
- N/D
- CD94/NKG2A, IL-10, and TGF-𝛽
- NKp30, NKp46, and IL-10
62
63
- Chronic HBV - CD8 T cells
- T cells




LCMV, lymphocytic choriomeningitis virus; N/D, not determined; IFNs, interferons; APC, antigen presenting cells; Tfh, follicular helper CD4 T cells; MCMV,
murine cytomegalovirus; DCs, dendritic cells; HCV, hepatitis C virus; HBV, hepatitis B virus.
TABLE 2 Regulation of immune responses by NK cells during autoimmunity
Species Disease/Model Target cell Molecules involved References





- NOD and streptozotocin-induced diabetes
- CD4 T cells
- CD4 T cells
- DCs, Th17, and Tr1
- CD4 T cells
- Th17 and Tfh
- CD8 T cells
- NKG2D, TRAIL
- perforin










Human - Juvenile idiopathic arthritis - CD4 T cells - CD38 and ADO 79
EAU, experimental autoimmuneuveitis; Th17, T helper 17 cells; Tr1, type 1 regulatory cells; IFN, interferon; EAE, experimental autoimmune encephalomyeli-
tis; Tfh, follicular helper CD4 T cells; PD-L1, programmed death-ligand 1; ADO, adenosine.
3 REGULATORY FUNCTIONS OF
NK CELLS DURING AUTOIMMUNITY
AND INFLAMMATION
Viral infections and the resulting antiviral immunity (in which NK
cells play an important role) are associated with the development
of several systemic autoimmune diseases.73 Paradoxically, in a
model of induced colitis, NK cells ameliorated the severity of the
disease through perforin-dependent elimination of effector CD4
T cells.74 Also, during the development of experimental autoim-
mune uveitis (EAU), IFN-𝛾 derived from NK cells was sufficient to
reduce the severity of the disease by suppressing the development
of Th17 responses though a circuit that involved a NK cell-derived
IFN-𝛾 induction of IL-27 production by DCs, which potentiated
IFN-𝛾 production by NK cells and induced IL-10 production by
both cells, and contributed to inhibit pathogenic Th17 responses.75
Therefore, NK cells can suppress immunopathology in different
models of autoimmune disorders, which highlights their dual role
as effector cells and as regulatory cells of the immune response
against pathogens.
Additional evidence unraveled a role of MHC-I class Ib molecule
Qa-1, which is recognized by the NK cell inhibitory receptor
CD94/NKG2A, in T cell protection from NK cell-mediated cyto-
toxicity. During the development of experimental autoimmune
encephalomyelitis (EAE), the interaction between Qa-1 on CD4 T cells
with CD94/NKG2A on NK cells prevented NK cell-dependent T cell
elimination and contributed to amplify the expansion of autoreactive
CD4 T cells, whereas antibody-mediated blockade of Qa-1 or adoptive
transfer of autoreactive Qa-1−/− CD4 T cells attenuated the severity
of the disease.76 In addition, in mice with collagen-induced arthritis
(which resembles human rheumatoid arthritis in some aspects) where
pathology is mediated by Th17 cells and Tfh cells that facilitate the
expansion of autoreactive B cells, blockade of NKG2A interaction
withQa-1 fostered NK cell-mediated elimination of Th17 and Tfh cells
in vitro and ameliorated arthritis progression in vivo.77 Moreover,
another subset of regulatory NK cells, characterized by the expression
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F IGURE 1 Direct inhibition of T cell responses by NK cells during viral infections. Following viral infections, activated NK cells can inhibit
T cell responses through different mechanisms. (A) Activating/inhibitory receptor-mediated recognition: activated NK cells show an enhanced
expression of activating receptors and reduced expression of inhibitory receptors, whereas activated T cells show an augmented expression of
ligands for activating receptors, which makes them susceptible to NK cell-mediated recognition and perforin-mediated lysis. Type I IFN signaling
on both cells, through modulation of the expression of such receptors and ligands, can protect activated T cells from NK cell-mediated lysis. (B)
Death receptor-mediated recognition. Caspase 8-mediated apoptosis can be induced onDR5-expressing T cells upon engagement of TRAIL onNK
cells (Apoptotic pathway); also, TRAIL signaling on NK cells can enhance the production of IL-15-induced granzyme B, which results in increased
perforin-mediated lysis of T cells (Non-apoptotic pathway), and (C) IL-10-mediated inhibition: NK cell-derived IL-10 can directly inhibit CD4 and
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F IGURE 2 Regulationof innate responsesbyNKcells during infections. Following some systemic viral, bacterial or parasite infections,NKcells
can secrete IL-10 which inhibits IL-12 production by dendritic cells (DCs). Moreover, NK cell-derived IL-10 inhibits the recruitment and activation
of myeloid cells
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TABLE 3 Regulation of immune responses by NK cells in cancer
Species Cell line/Tumor Target cell Molecules involved References
Mouse - RMA and B16F10
-MC57










- PD-L1 and IL-18












- CD4 T cells










RMA, T cell lymphoma cell line; B16F10, melanoma cell line; iNOS, inducible nitric oxide synthase; MC57, mouse fibrosarcoma cell line; CT26, colon carci-
noma cell line; LN7, metastatic cell line of Lewis lung carcinoma; Treg, regulatory T cell; NSCLC, non-small cell lung cancer; N/D, not determined.
of CD117 (c-Kit) and programmed death-ligand 1 (PD-L1) and that
could kill activated CD8 T cells (but not CD4 T cells) through PD-
L1-recognition in vitro and in vivo, was described.78 These CD117+
NK cells could be generated in vitro upon IL-18 stimulation of naïve
CD117− NK cells and were detected in spleens and lymph nodes of
healthy mice and, at lower frequencies, in NOD mice. Remarkably,
adoptive transfer of IL-18-stimulated NK cells (presumably containing
an increased abundance of these CD117+ NK cells) reduced the sever-
ity of streptozotocin-induced diabetes in mice in a PD-L1-dependent
manner.78 Also, CD38+CD56bright NK cells can inhibit CD4 T cell pro-
liferation through the production of adenosine, whereas CD56bright
NK cells from the synovial fluid of patients with juvenile idiopathic
arthritis express lower amounts of CD38 and fail to inhibit CD4 T cell
proliferation, confirming the role of CD38 expressed by NK cells in the
regulation of T cell proliferation.79
Taken together, these studies strongly point to the existence of
NK cells with a regulatory role that, through different and per-
haps overlapping and/or redundant mechanisms, contribute to an
optimal sizing of the magnitude of the T cell-mediated immune
response against pathogens, limiting the damage to self-tissues and
whose interference may tilt the balance toward immunopathol-
ogy in different conditions (summarized in Tables 1 and 2 and
Figs. 1 and 2).
4 REGULATORY FUNCTIONS OF NK CELLS
IN ANTITUMOR IMMUNITY
The tumor microenvironment induces multiple phenotypic and func-
tional modifications on immune cells. Tumor-infiltrating CD8 T cells
display an exhausted phenotype, transcriptionally similar to exhausted
CD8 T cells from chronic LCMV-infected mice.81 Also, NK cells
infiltrating tumors exhibit an altered phenotype and are often
dysfunctional.82 Despite several studies that unraveled the regula-
tory functions of NK cells during infections and that were discussed
above, less is known about regulatory NK cells during tumor progres-
sion. Early work using a mouse syngeneic model of RMA lymphoma
revealed that the depletion of NK cells induced enhanced antigen pre-
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F IGURE 3 Direct inhibition of T cells by NK cells during antitu-
mor immune responses. Tumor progression leads to modifications in
NK cell phenotype and function, making them able to directly inhibit T
cell responses.NKcells cankill antigen-specificCD8Tcells in aNKG2D
and perforin-dependentmanner and can inhibit T cell proliferation and
effector functions in an NKp46-dependent manner. Also, a population
of IL-10-producing NK cells (characterized by the expression of CD73)
is able to inhibit CD4 T cell proliferation and IFN-𝛾 production in an
IL-10-dependent manner
CD8 T cells, enhanced tumor-specific lysis and IFN-𝛾 production.83 It
was later observed that the interaction betweenTRAIL onNKcells and
TRAIL-R2onDCs induced the expressionof several immunoregulatory
molecules such as IL-10, iNOS, and arginase-1 in DCs, which resulted
in arginase-1-dependent inhibition of the DCs cross-priming ability of
CD8 T cells against tumor-associated antigens.84
Consistent with these results, we observed that following subcu-
taneous implantation of immunogenic MC57 tumor cells transduced
to express the model antigenic peptide SIYRYYGL (SIY), NK cell
depletion led to a significantly higher frequency of spontaneously
activated SIY-specific CD8 T cells, with enhanced IFN-𝛾 production
and cytotoxic capability.85 Furthermore, NK cells also constrained
the expansion of an effector memory CD8 T cell population, which













F IGURE 4 Indirect inhibition of antitumor T cell responses by NK cells through regulation of DCs maturation and/or cross presentation.
During tumor progression NK cells can modulate DCs activation, resulting in attenuated T cell priming. The interaction between TRAIL on NK
cells and DR5 on DCs induces the expression of arginase-1 (Arg-1) on DCs, which inhibits the cross-presentation of tumor antigens, and results in
reduced cross-priming of CD8 T cells. Tumor-infiltrating NK cells can also express PD-L1, which through interaction with PD-1 expressed on DCs,
limits DCsmaturation, resulting in diminished CD8 T cell priming
resulted in diminished recall response and reduced tumor control after
a secondary tumor challenge with the poorly immunogenic B16.SIY
tumor.85 Analysis of tumor-infiltrating and tumor-draining lymph
node NK cells showed an up-regulated expression of the inhibitory
molecule PD-L1 compared with peripheral blood NK cells from the
same animals or from tumor-free mice. Mechanistically, DCs from
tumor-bearing mice exhibited PD-1 expression and NK cell inhibited
DCs maturation through PD-L1, explaining their reduced ability to
induce CD8 T cell priming. Together, these data suggest that PD-L1hi
NK cells that emerge during tumor growth can directly regulate
DCs maturation resulting in a reduced ability to support CD8 T cell
priming and recall responses against tumor antigens.85 In another
study, CD117+PD-L1+ NK cells were shown to be induced by B16 and
CT26-derived IL-18, and adoptive transfer of these NK cells resulted
in reduced numbers of DCs and promoted the growth of both tumors
in a PD-L1 dependentmanner.86 The presence of PD-L1+ NK cells was
also described in patientswith acutemyeloid leukemia, and anti-PD-L1
antibodies promoted enhanced NK cell effector functions and a better
control of PD-L1− tumors in a PD-1 independent-manner.87
Additionally, after immunization of OT1 mice with OVA, NK cells
could kill antigen-specific CD8 T cells in a NKG2D and perforin-
dependent manner, whereas immunization in the absence of NK cells
resulted in a higher frequency of OT1 CD8 T cells and an enhanced
memory response that resulted in an improved tumor control when
immunized mice were challenged with B16.OVA tumor cells.88 A dif-
ferent and more indirect mechanism for regulatory NK cells was
described in a model of Lewis Lung carcinoma where NK cells induced
Treg recruitment through CCL22 secretion, which in turn could con-
tribute to immunoregulation.89
In humans, the presence of a population of CD3−CD56+ cells in cul-
tures of tumor-infiltrating lymphocytes (TIL) from patients with pri-
mary high-grade serous ovarian cancer was associated with reduced
numbers of CD4 and CD8 T cells. These regulatory CD3−CD56+
cells showed an expression profile overlapping with those of NK
cells and other ILCs, expressed NKG2D, NKp30 and NKp46, and
suppressed TIL proliferation and TNF-𝛼 and IFN-𝛾 production in an
NKp46-dependent manner Moreover, the presence of these regula-
tory CD3−CD56+ cells in TIL cultures correlated with a reduction
in the time to relapse.90 In addition, a higher frequency of a pop-
ulation of circulating NKp46+CD56dimCD16+ NK cells was associ-
ated with a decreased overall survival in patients with non-small cell
lung cancer (NSCLC), and NKp46 blockade enhanced IFN-𝛾 produc-
tion by tumor antigen-specific CD4 T cells in cultures of patient-
derived PBMC.91
A recent study shows that tumor-infiltrating NK cells from breast
cancer patients display an increased expression of the 5′ ectonu-
cleotidase CD73, accompanied by up-regulation of other immune
checkpoint receptors such as LAG-3, VISTA, PD-1, and PD-L1.92 The
induction of enzymatically active CD73 was dependent on 4-1BBL
recognition on tumor cells and CD73+ NK cells were able to inhibit
CD4 T cell proliferation and IFN-𝛾 production, but the inhibition was
not dependent on the production of extracellular adenosine by CD73
activity. Instead, STAT3-mediated IL-10 production by these CD73+
NK cells accounted for the suppressive effect.92 Consistent with these
results, IL-10-producing NK cells were detected in the circulation of
a different cohort of breast cancer patients.93 Another study demon-
strated that, in melanoma patients, a high frequency of circulating
CD56bright NK cells with an altered phenotype, including increased
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expression ofCD38 (another ectoenzyme involved in the noncanonical
production of adenosine94) is associated with a worsened outcome.95
Together, these studies start to outline the role of NK cells in the
direct and indirect mechanisms involved in regulation of antitumor
adaptive immune responses in mouse and humans (summarized in
Table 3 and Figs. 3 and 4).
5 CONCLUDING REMARKS
NK cells can provide multiple levels of inhibition for T cell responses,
including indirect inhibition through targeting of DCs, direct lysis of
activated T cells or regulation of T cell effector function through the
secretion of immunoregulatory cytokines or the expression of discrete
cell surface receptors not involved in direct target cell lysis. Moreover,
the regulation ofCD4T cell responses has also implications on the gen-
eration of B cell immunity. Regardless of the ultimate mechanism used
to constrain the adaptive immune response, recently elucidated reg-
ulatory functions of NK cells may constitute a mechanism to prevent
overactivation of adaptive immune cells during chronic infections that
otherwise may lead to immunopathology. However, some tumors may
hijack these physiologic regulatory functions, coopting their mecha-
nism to promote immune tolerance and tumor escape. Therefore, the
elucidation of phenotypic markers that define NK cells with regula-
tory functions may lead to the development of novel modalities of
immunotherapy in which a timely depletion of NK cells with regu-
latory functions may improve the efficacy of current immunothera-
pies. Also, a more comprehensive elucidation of the mechanisms that
drive the generation and action such NK cells with regulatory func-
tions will probably contribute to the development of strategies aimed
at the manipulation of their expansion and effector functions in differ-
ent pathologic conditions with the ultimate goal of appropriately siz-
ing an optimal adaptive immune responses in cancer and chronic viral
infections, and, on the other hand, promote tolerance in transplants
and autoimmune disorders.
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